

F 522

## Chemical Properties


CAS No. : 25134-54-7

Formula: C<sub>10</sub>H<sub>19</sub>NO<sub>2</sub>

Molecular Weight: 185.26

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	F 522 (DA-3031) is a recombinant human granulocytic colony-stimulating factor that is expected to last longer than unmodified fegestine for the prevention of breast cancer. DA-3031 is a newly developed pegylated non - gostin.
Targets(IC50)	Others

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	5.3978 mL	26.9891 mL	53.9782 mL
5 mM	1.0796 mL	5.3978 mL	10.7956 mL
10 mM	0.5398 mL	2.6989 mL	5.3978 mL
50 mM	0.108 mL	0.5398 mL	1.0796 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Ahn LY, Shin KH, Lim KS, Kim TE, Jeon H, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects. *Clin Drug Investig.* 2013 Nov;33(11):817-24. PubMed PMID: 24078278.

Park KH, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. *Invest New Drugs.* 2013 Oct;31(5):1300-6. doi: 10.1007/s10637-013-9973-4. Epub 2013 May 16. PubMed PMID: 23677653.

Wadhwa M, Bird C, Dougall T, Rigsby P, Bristow A, Thorpe R; participants of the study. Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): report of an international collaborative study. *J Immunol Methods.* 2015 Jan;416:17-28. doi: 10.1016/j.jim.2014.10.005. Epub 2014 Oct 25. PubMed PMID: 25450254; PubMed Central PMCID: PMC4334095.

Park KH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Park S, Lee SI, Jung KH, Kim YS, Seo JH. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer. *Support Care Cancer.* 2017 Feb;25(2):505-511. doi: 10.1007/s00520-016-3429-2. Epub 2016 Oct 6. PubMed PMID: 27709313.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481